Combating evolution with intelligent design: the neoglycoside ACHN-490.
about
New developments in aminoglycoside therapy and ototoxicity10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaBreaking the Spell: Combating Multidrug Resistant 'Superbugs'Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infectionsTargeting Antibiotic ResistanceComparing aminoglycoside binding sites in bacterial ribosomal RNA and aminoglycoside modifying enzymes.Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.Investigational antimicrobial agents of 2013.The evolving role of chemical synthesis in antibacterial drug discovery.Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjectsPlazomicin: an investigational therapy for the treatment of urinary tract infections.Synthesis of 4'-aminopantetheine and derivatives to probe aminoglycoside N-6'-acetyltransferaseSimplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patientsCurrent epidemiology and growing resistance of gram-negative pathogens.Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.MexXY multidrug efflux system of Pseudomonas aeruginosa.A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosidesNew antibiotic agents in the pipeline and how they can help overcome microbial resistance.Riboswitch control of induction of aminoglycoside resistance acetyl and adenyl-transferasesEpidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipientsAntibiotics in development targeting protein synthesis.Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance.Combating multidrug-resistant Gram-negative bacterial infections.New antibacterial agents: patent applications published in 2010.Natural product and natural product derived drugs in clinical trials.New treatment options for hearing loss.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Emerging resistance to aminoglycosides in lactic acid bacteria of food origin-an impending menace.Parallel pathways in the biosynthesis of aminoglycoside antibiotics.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Aminoglycosides: An Overview.Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.A fused [3.3.0]-neoglycoside lactone derived from glucuronic acid.The evolution of substrate discrimination in macrolide antibiotic resistance enzymes.Amikacin: Uses, Resistance, and Prospects for Inhibition.
P2860
Q24599985-DD104812-3D06-4428-9074-89753E4EB8BCQ24601746-25664942-5AEC-4C13-8CCB-3DE373ED6D17Q26765868-A49A194E-5F92-47C4-B026-9DB0602ED83DQ26859978-CA16A317-7D0F-4A9D-9017-860F1A5F9C38Q28078130-BFB3255E-2971-42A4-82E6-F656F671CEB3Q30558517-5F7DD2D4-8595-4892-87DD-371575DD58B0Q34058006-CEA54163-BAFB-4536-BEFC-D23D9B919A9DQ34269044-C8F09DAE-E7A9-4B3B-96B1-A8050B3334E5Q34375204-B27ADF02-EB99-4265-848B-B118610E1E8EQ34427652-B37258D4-D776-4FE4-817A-2CFAF5E21489Q34632230-73FF4E7E-660F-43AD-A3EB-1A0FB6F70179Q34673393-C638CFD3-2866-45C3-8C3A-A1B5A5B52EECQ34882031-FA71C465-FEE5-4CBC-819C-100DA16E6828Q35191383-78CBAC17-DE43-47ED-98E3-592998D29733Q36025192-D8456EFC-A300-4EA4-B5E7-CDD245E7367FQ36107990-C115E239-BBB0-4F05-AB8D-C76FE5A9A893Q36450695-DD27FB91-6488-4FD5-9664-52FF8BD59ECDQ36726249-D37D8074-33AE-4ED2-81EB-A3531EF08D6AQ36845895-585CC451-10A2-49D5-8B28-4078EB69DEF5Q37278886-E1B2D81F-11A9-4BA4-9423-EED222FDC08BQ37639165-191BB1C3-B237-431F-9A16-CA60700EACE2Q37970724-B78BDAAE-7A40-43A0-9CC6-0659A6DF8106Q38117380-FAC0F1B3-7ABF-4A54-BCC0-12B9605726E7Q38161570-7E45B0F9-80E5-403A-A900-4619F4DA4E07Q38162949-12A8C780-2972-4718-A379-5A7AB95C7B1CQ38247457-B73809E0-0D35-4103-A6F3-86074CDC01C0Q38384722-0E87756D-9F5C-4259-BCA5-FE88E2521CE4Q38648594-565D04C0-2DF5-49EA-979F-941AB6FAB453Q38657199-3D81EF2E-E09E-4AA7-B074-C730EDC90314Q38670416-9973CB69-02B0-4E5E-A5FB-7F4AE64072BEQ38783043-8711F4D9-A095-4475-8E47-25B763E627DFQ38851189-E9945DAA-524C-42B8-8F68-44F798281FB4Q41992420-0B0BB45C-9CC2-4158-9A09-93DD470AD0E2Q42595068-2D1F030C-CDF4-43C0-A2A2-C6D3C189857CQ49306295-633E73F1-A3C1-4296-900A-02F9252A1223Q52744431-9F7F4A18-CFD4-4B64-9B3F-56EFAAFE6090
P2860
Combating evolution with intelligent design: the neoglycoside ACHN-490.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combating evolution with intelligent design: the neoglycoside ACHN-490.
@en
Combating evolution with intelligent design: the neoglycoside ACHN-490.
@nl
type
label
Combating evolution with intelligent design: the neoglycoside ACHN-490.
@en
Combating evolution with intelligent design: the neoglycoside ACHN-490.
@nl
prefLabel
Combating evolution with intelligent design: the neoglycoside ACHN-490.
@en
Combating evolution with intelligent design: the neoglycoside ACHN-490.
@nl
P1476
Combating evolution with intelligent design: the neoglycoside ACHN-490.
@en
P2093
Eliana S Armstrong
George H Miller
P304
P356
10.1016/J.MIB.2010.09.004
P577
2010-10-01T00:00:00Z